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a  b  s  t  r  a  c  t
Aim of the work: To compare the effect of adding short course follicular phase dexametha-
zone to clomiphene citrate versus increasing clomiphene citrate dose in cases of resistance.
Materials and methods: The study was conducted on 85 with polycystic ovary syndrome who
were  resistant to 150 mg clomiphene citrate daily for 5 days for 3 months and were attending
El  Shatby Maternity University Hospital in the period between September 2011 and May
2013. These patients were randomly allocated by closed envelope method into one of the
two  groups: Group I: 44 patients received 200 mg daily of clomiphene citrate from day 3 and
for  5 days together with 2 mg dexamethazone daily from day 3 and for 10 days. Group II:
41  patients received 200 mg daily of clomiphene from day 3 and for 5 days.
Results: We  found that a signiﬁcant higher rate of ovulation was reported in the dexamet-
hazone group compared to clomphine citrate only group, endometrial thickness was more
favorable in dexamethazone group than the other group, mid luteal serum progesterone was
a  higher level in dexamesathone group compared to the other group and serum pregnancy
rate was higher in dexamethazone group than the other group.
Conclusion: Although the mechanism underlying the beneﬁcial effects of dexamesathone is
not  exactly understood, it is apparent from our data that dexamesathone therapy during
the  follicular phase can enhance follicular development and ovulation. Dexamethazone
(corticosteroids) therapy combined with clomphine citrate can improve folliculogenesis,
ovulation, and pregnancy rate in clomphine citrate resistant polycystic ovary syndrome.©  2015 Sociedade Brasileira de Reproduc¸ão Humana. Published by Elsevier Editora Ltda.
All rights reserved.∗ Corresponding author.
E-mail: Ahmedsamyagwany@gmail.com (A.S. El-Agwany).
ttp://dx.doi.org/10.1016/j.recli.2015.10.002
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Administrac¸ão  de  dexametasona  na  fase  folicular  em  pacientes  com





r  e  s  u  m  o
Objetivo do estudo: Comparar o efeito da adic¸ão de dexametasona em curso de curta durac¸ão
ao  citrato de clomifeno na fase folicular versus aumento da dose de citrato de clomifeno em
casos  de resistência.
Materiais e métodos: O estudo foi realizado em 85 mulheres com síndrome do ovário policís-
tico  e resistentes à medicac¸ão com citrato de clomifeno 150 mg/dia durante 5 dias por
3  meses e que se encontravam em tratamento na Maternidade do Hospital Universitário
El  Shatby no período entre setembro de 2011 e maio de 2013. Essas pacientes foram desig-
nadas  randomicamente pelo método do envelope fechado em um entre dois grupos: Grupo
I:  44 pacientes medicadas com citrato de clomifeno 200 mg/dia a partir do terceiro dia e
durante 5 dias, juntamente com dexametasona 2 mg/dia a partir do terceiro dia e durante
10  dias; Grupo II: 41 pacientes medicadas com citrato de clomifeno 200 mg/dia a partir do
terceiro dia e durante 5 dias.
Resultados: Constatamos que um percentual signiﬁcativamente mais elevado de ovulac¸ões
foi informado no grupo de dexametasona, em comparac¸ão com o grupo medicado exclusiva-
mente com citrato de clomifeno; em comparac¸ão com o outro grupo, no grupo das mulheres
tratadas com dexametasona a espessura do endométrio se revelou mais favorável, foram
observados níveis séricos mais altos de progesterona na metade da fase lútea, e o percentual
de  gestac¸ão sérica foi mais elevado.
Conclusão: Embora o mecanismo subjacente aos efeitos benéﬁcos obtidos com o uso de
dexametasona não tenha ainda sido completamente esclarecido, ﬁca evidente, com base
em  nossos dados, que o tratamento com dexametasona durante a fase folicular pode mel-
horar o desenvolvimento dos folículos e a ovulac¸ão. A terapia com dexametasona (um
corticosteroide) em combinac¸ão com citrato de clomifeno pode melhorar os percentu-
ais  de foliculogênese, de ovulac¸ão e de gestac¸ões em mulheres com SOPC resistentes ao
citrato de clomifeno.
© 2015 Sociedade Brasileira de Reproduc¸ão Humana. Publicado por Elsevier Editora
Ltda. Todos os direitos reservados.Introduction
Chronic anovulation is one of the examples of ovulatory
dysfunction. The polycystic ovary syndrome (PCOS) is the
most obvious and common heterogeneous endocrine condi-
tion associated with chronic anovulation affecting 4–6% of
reproductive age group.1 It is one of the examples of eugo-
nadotropic eu-estrogenic anovulation, as it represents 75–80%
of all ovulatory disorders. It was discovered by both Stein and
Leventhal in 1935 by description of seven patients with amen-
orrhea, hirsutism, and enlarged polycystic ovaries.
Because the diagnostic criteria for PCOS have changed,
it is difﬁcult to obtain consistent prevalence information.
Approximately 22% of women in the general population
have polycystic ovaries as an incidental ﬁnding on ultra-
sound examination. A study using the NIH/NICHHD criteria
(which relied on oligomenorrhoea/amenorrhoea and clini-
cal/biochemical evidence of hyperandroge-naemia) estimated
that 6.2% of white and 3.4% of black women attending
for a mandatory pre-employment medical examination had
PCOS.2–8Weight loss, exercise, and lifestyle modiﬁcations have been
proven effective in restoring ovulatory cycles and achiev-
ing pregnancy in overweight women with PCOS and shouldbe the ﬁrst-line option for these women. Morbidly obese
women should seek expert advise about pregnancy risk.
Clomiphene citrate (CC) has been proven effective in ovulation
induction for women with PCOS and should be consid-
ered the ﬁrst-line therapy. Patients should be informed that
there is an increased risk of multiple pregnancies with
ovulation induction using CC. The CC will induce ovula-
tion in 60–80% of properly selected patients. The likelihood
of response decreases with increasing age and body mass
index and the extent of associated hyperandrogenemia in
anovulatory women. Women with amenorrhea are more
likely to conceive than those with oligomenorrhea, possi-
bly because infertile women who menstruate also likely
ovulate infrequently and are more  likely to have other co-
existing infertility factors. Cumulative pregnancy rates of
70–75% can be expected over 6 cycles of treatment. There-
after, cycle fecundability falls substantially. When pregnancy
is not achieved within 3–6 of CC induced ovulatory cycles,
the infertility investigation should be expanded to exclude
other infertility factors, or to change the overall treatment
strategy. CC resistance: It is deﬁned as failure to ovulate
in response to CC on doses of 150 mg/day after 3 cycles.
The CC resistance is an unpredictable and unpreventable
event. It is virtually impossible to predict who  will respond
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n a standard regimen for management of CC resistant PCO
atients.9
Several alternatives for those who are CC resistant: weight
oss and lifestyle modiﬁcations: Obesity is strongly associ-
ted with PCOS and may be present in up to 50% of cases.
bese women with PCOS are more  likely than thin women
ith PCOS to suffer from anovulation.10 This effect on ovu-
ation may be secondary to insulin resistance, which in turn
esults in hyperinsulinemia and stimulation of excess andro-
en production from the ovaries.11 Lifestyle modiﬁcation is
he ﬁrst line treatment in an evidence-based approach for
he management of the majority of PCOS women who are
verweight.12 Gonadotropins: ovulation induction for women
ith anovulatory PCOS using gonadotropin therapy is based
n the physiological concept that initiation and mainte-
ance of follicle growth may be achieved by a transient
ncrease in follicle-stimulating hormone (FSH) above a thresh-
ld dose for sufﬁcient duration to generate a limited number
f developing follicles.12 Traditionally, ovulation induction
ith gonadotropins has been used as a second line treat-
ent for CC resistant PCOS women; however, it is expensive,
equires extensive monitoring and associated with signiﬁ-
antly increased risk for ovarian hyperstimulation syndrome
OHSS) and multiple pregnancy.13
Laparoscopic ovarian diathermy (LOD): LOD is currently
ccepted as a successful second line treatment for ovu-
ation induction in CC-resistant PCOS being as effective
s gonadotropin treatment and is not associated with an
ncreased risk of multiple pregnancy or OHSS.13 Insulin-
ensitizing drugs: approximately 50–70% of all women with
COS have some degree of insulin resistance.14 Hyperinsuline-
ia  probably contributes to the hyperandrogenism which is
esponsible for the signs and symptoms of PCOS.15 Metformin,
 biguanide, is now the most widely insulin sensitizer used for
vulation induction in women with PCOS. Third-generation
romatase inhibitors (AIs): third-generation AIs (anastrozole,
etrozole, exemestane) are approved adjuvants for treatment
f estrogen-receptor – positive breast cancer16 that were ﬁrst
sed in ovulation induction in anovulatory women in 2001.
vidence suggests that nonsteroidal AIs, speciﬁcally letrozole
nd anastrozole, have ovulation-inducing effects by inhibi-
ing androgen-to-estrogen conversion. Centrally, this effect
eleases the hypothalamic/pituitary axis from estrogenic neg-
tive feedback, increases gonadotropin secretion, and results
n stimulation of ovarian follicle maturity. Moreover, periph-
rally, AIs may increase follicular sensitivity to FSH. Oral
ontraceptives: Branigan and Estes in a randomized controlled
rial (RCT) showed that the suppression of the hypothala-
ic  pituitary-ovarian axis for 2 months with combined oral
ontraceptives (COC) (0.03 mg  of ethinyl estradiol and 0.15 mg
f desogestrel) followed by CC, at dosage of 100 mg/day on
ays 5–9 of the cycle, improved ovulation and pregnancy
ates in CC resistant women in comparison with repeated
ycles of CC alone. N-acetyl-cysteine (NAC): NAC is a mucolytic
rug. Fulghesu et al. demonstrated that long term NAC treat-
ent (1.8 g/day for 5–6 weeks) was associated with signiﬁcantncrease in insulin sensitivity and reduction in insulin levels,
estosterone and free androgen index (FAI) in hyperinsuline-
ic  PCOS. Rizk et al. showed that the combination of NAC
1.2 g/day) with CC (100 mg/day) for only 5 days signiﬁcantly 0(3):115–120 117
increased both ovulation and pregnancy rates in obese women
with CC-resistant PCOS compared with placebo (49.3% vs.
1.3% and 21.3% vs. 0, respectively). Dexamethazone ther-
apy: dexamethazone therapy during the follicular phase has
been described without any side effects or serious events.
Parsanezhad et al. in a double-blind RCT, showed the safety
and the efﬁcacy of a high-dose short course of dexametha-
zone for inducing ovulation in 230 CC-resistant patients with
PCOS and normal DHEAS levels. They reported signiﬁcantly
higher ovulation and pregnancy rates in those who  received
200 mg of CC (days 5–9) and 2 mg of dexamethazone (days
5–14) compared with CC alone (88% vs. 20% and 40.5 vs. 4.2%,
respectively). In these patients, dexamethazone reduced cir-
culating dehydroepiandrosterone sulfate (DHEAS), total and
free testosterone (T), and luteinizing hormone (LH) levels and
the LH/FSH ratio after 2 weeks of treatment. These results were
further conﬁrmed in another RCT. Bromocriptine: currently,
evidence suggests that PCOS and hyperprolactinaemia are two
distinct entities without a pathophysiological link. Bromocrip-
tine administration provided no beneﬁt in CC-resistant PCOS
patients with normal prolactin levels, receiving 150 mg  CC
(days 5–9) and bromocriptin continuously administrated at a
dosage of 7.5 mg  daily. In vitro fertilization: should be reserved
for women with PCOS who fail other modalities or who  have
other indications for IVF treatment.14–17
The aim of the present study was to compare the efﬁcacy
of two different regimens of CC in the treatment of patients
with PCOS resistant to the 150 mg  dose of CC.
Patients
The study was conducted on 85 PCOS patients attended El-
Shatby University Maternity Hospital in the period from 4/2012
to 9/2013 with the following inclusion criteria: PCOS diagnosis
according to the Rotterdam criteria,3 age from 19 to 35 years
old and no ovulation following a regimen of CC 100 mg  for
5 days (starting from day 3). Exclusion criteria: other causes of
infertility than PCOS and other endocrinal disorders.
Patients were allocated to one of the following two groups:
Group I: including 41 PCOS patients who received 200 mg  CC
tablets for 7 days starting from day 3. Group II: including 44
PCOS patients who received 200 mg  CC and 2 mg  dexamet-
hazone/daily for 10 days starting from day 3. The study was
approved by the University Ethics Committee and a signed
written informed consent was obtained from each patient.
Methods
Following approval of the Medical Ethical Committee, obtain-
ing a signed informed written consent and explanation of
the procedures and aim of the study, all women included in
this study were subjected to: complete history taking, gen-
eral medical examination; including a systematic endocrinal
review, local gynecological examination, transvaginal ultra-
sound examination in order to evaluate ovarian volume, antral
follicles count, uterus and endometrial thickness and pattern.
Hormonal assays on day 2: FSH and LH levels, T levels and
thyroid-stimulating hormone (TSH) and prolactin levels.
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Table 1 – Comparison between the two studied groups regarding demographic.
Group I Group II p-Value
n (44) n (41)
Age in years (mean ± SD) 27.75 ± 4.32 26.71 ± 4.03 0.26
Gravidity (mean ± SD) 0.48 ± 0.68 0.49 ± 0.88 0.939
Parity (mean ± SD) 0.13 ± 0.40 0.21 ± 0.47 0.383
Abortion (mean ± SD) 0.3750 ± 0.627 0.302 ± 0.741 0.632
56 ± 
32 ± Duration of marriage in years (mean ± SD) 4.
Weight in kg (mean ± SD) 72.
Follow-up: by folliculometry starting from day 11 then day
after day for 1 week, endometrial thickness, mid  luteal serum
progesterone and chemical pregnancy.
Data were fed to the computer and analyzed using IBM
SPSS software package version 20.0. Qualitative data were
described using number and percent. Quantitative data were
described using mean and standard deviation, median, min-
imum and maximum. Comparison between different groups
regarding categorical variables was tested using Chi-square
test. When more  than 20% of the cells have expected count
less than 5, correction for chi-square was conducted using
Fisher’s exact test or Monte Carlo correction. The distribu-
tions of quantitative variables were tested for normality using
Kolmogorov–Smirnov test, Shapiro–Wilk test and D’Agstino
test. For normally distributed data, comparison between
different groups was analyzed using F-test (ANOVA). For
abnormally distributed data, Kruskal Wallis test was used to
compare between different groups. Signiﬁcance test results
are quoted as two-tailed probabilities. Signiﬁcance of the
obtained results was judged at the 5% level.
Results
There was no statistically signiﬁcant difference between the
groups regarding age, gravidity, parity, abortion, duration of
marriage and weight (Table 1). There was statistical differ-
ence between both groups with larger endometrial thickness
(7.67 vs. 6.61 mm)  and mid  luteal serum progesterone (9.7 vs.
8.2 ng/mL) in Group II (Table 2). There was signiﬁcant differ-
ence between both groups with higher pregnancy rate (23.3%
vs. 2.5%) in Group II (Table 3). There was signiﬁcant differ-
ence between both groups with higher ovulation rate (51.2%
vs. 12.5%) in Group II (Table 4).
DiscussionIn 2002, the novel use of dexamethazone (high dose, short
course) for inducing ovulation in anovulatory women with
PCOS and normal DHEAS was reported. Dexamethazone was
Table 2 – Comparison between the two studied groups regardin
Endometrial thickness at time of ovulation in mm (mean ± SD) 
Mid luteal serum progesterone in pg/mL (mean ± SD) 
a Statistically signiﬁcant difference.2.468 4.14 ± 2.154 0.416
10.36 72.86 ± 12.86 0.816
very  well tolerated as no patients complained of any side
effect. Dexamethazone therapy during the follicular phase has
been described without any side effects or serious sequelae
(Tables 1–4). It was found that there were no differences in ovu-
latory response to dexamethazone therapy between women
with or without DHEAS excess. On the other hand, in 1984, it
was reported that the effect of dexamethazone was largest in
women with raised DHEAS levels.10–13
The recent systematic review of the Cochrane library
reported that the use of dexamethazone as an adjunct to CC
appears promising improvement in the pregnancy rate when
compared to CC alone.
In our study, we used comparison between 2 different
regimens for management of PCOS resistant to 150 mg CC.
The ﬁrst group included 44 females received 200 mg CC in
and the other with addition of 2 mg  dexamethazone daily
for 10 days starting from day 3. Then follow up was done by
TVUS, mid  luteal serum progesterone and serum pregnancy
test. We found that a signiﬁcant higher rate of ovulation
was reported in the dexamethazone group compared to
CC group. As regard to endometrial thickness was more
favorable (in dexamethazone group than CC only. As regard
to mid  luteal serum progesterone it was found higher level
in dexamesathone group (compared to CC only. As regard
to serum pregnancy it was higher in dexamethazone group
than CC only. Our result is in agreement with Parsanezhad
et al.’s, Elnashar et al.’s and Al-Shaikh’s study. Parsanezhad
et al.’s study was done in 2002 at Shiraz University of Medical
Sciences, Shiraz, Iran on 230 PCOS females resistant to 250 mg
CC divided randomly to two groups. First group (control
group) received 200 mg  of CC from cycle days 5 to 9 and
four tablets of placebo (folic acid) from cycle days 5 to 14.
Second group received 200 mg  of CC from cycle days 5 to 9 and
2 mg  of dexamethazone tablets from cycle days 5 to 14. The
result of this study conﬁrmed that high-dose dexamethazone
during the follicular phase resulted in a high rate of ovulation
with a pregnancy rate of 40% with sharp contrast to the
low ovulation and pregnancy rates seen in the other group.
Elnashar et al.’s study done in 2006 at the Department of
Obstetrics and Gynecology, Benha University Hospital, Benha,
g U/S ﬁndings.
Group I Group II p-value
n (44) n (41)
6.6100 ± 0.70303 7.6721 ± 1.59737 0.001a
8.2425 ± 1.88882 9.7256 ± 3.10875 0.01a
r e p r o d c l i m . 2 0 1 5;3  0(3):115–120 119
Table 3 – Pregnancy rate in the two studied groups.
Group Total
Group I Group II
n (44) n (41)
Pregnancy Negative
Count  39 33 72
Count 39 33 72
% within group 97.5% 76.7% 86.7%
Positive
Count 1 10 11
Count 1 10 11
% within group 2.5% 23.3% 13.3%
Total Count 40 43 83
% within group 100.0% 100.0% 100.0%
2 7.76
p 0.005
Table 4 – Ovulation in the two studied groups.
Group Total
Group I Group II
n (44) n  (41)
Ovulation by US Negative
Count 35 21 56
% within group 87.5% 48.8% 67.5%
Positive
Count 5 22 27
% within group 12.5% 51.2% 32.5%
Total Count 40 43 83

























Ip-Value for F-test (ANOVA) for comparing between the different stud
a Statistically signiﬁcant at p ≤ 0.05.
gypt on 80 PCOS females resistant to CC divided randomly
o two groups. First group received CC 100 mg/day from day 3
o day 7 of the cycle and dexamethazone 2 mg/day from day
 to day 12 of the cycle. Second group received CC 100 mg/day
rom day 3 to day 7 of the cycle and placebo (folic acid tablets)
rom day 3 to day 12 of the cycle. In this study, a signiﬁcant
igher rate of ovulation was reported in the dexamethazone
roup (75%) than in placebo group (15%). Similarly the mean
umber of follicles >18 mm at the time of human chorionic
onadotropin (hCG) administration was signiﬁcantly higher
n the dexamethazone group than in the placebo group, the
ean endometrial thickness and the pregnancy rate in the
examethazone group (8.8 mm)  was signiﬁcantly higher than
n the placebo group (7 mm)  and a higher rate of pregnancy in
examethazone group (40%) than in placebo group (5%).12–14
Al-Shaikh’s study was done at Infertility Clinic of Babil
ospital between April 2008 and October 2009 on 43 PCOS
emales resistant to 100 mg CC. First group (31 patients)
eceived CC 100 mg/day from day 3 to day 7 of the cycle
nd prednisolone 10 mg/day orally in two divided doses from
ay 2 to day 12 of the cycle. Second group (12 patients)
eceived CC 150 mg/day from day 3 to day 7 of the cycle.
n this study, a signiﬁcant higher rate of ovulation wasoup.
reported in the prednisolone group 23 (74.19%) versus 2
(16.66%) in CC only group and in the clomiphene plus
prednisolone treatment group there is a signiﬁcant improve-
ment in the pregnancy rate when compared to CC alone 17
(54.84%) versus 1 (8.33%) respectively (Tables 1–4). There are a
number of potential mechanisms by which dexamethazone
(corticosteroids) may affect ovarian function. Dexametha-
zone acts directly on the pituitary gland to suppress the
action of estradiol, which may be involved in the pro-
cess of induction of ovulation by glucocorticoid–clomiphene
treatment. Dexamethazone may directly inﬂuence follic-
ular development. Dexamethazone may act indirectly by
increasing serum GH, serum insulin-like growth factor (IGF-1)
and consequently follicular ﬂuid IGF-1 concentrations. Dex-
amethazone enhances the FSH-stimulated follicular steroid
production. The synergism of Dexamethazone (corticoste-
roids) with FSH in follicular progesterone production and its
inhibition by transforming growth factor- (TGF-)  indicate
that glucocorticoid and TGF- interaction may be necessary
for granulosa cell differentiation as follicle matures through
pre-antral stages.18 Casterlin et al. found that the major-
ity of pregnancies (97%) occurred when the endometrial
thickness was 7–11 mm,  and the miscarriage rate doubles
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when the endometrial thickness measures <7 mm.  Immuno-
suppression, leading to a favorable endometrial environment,
was the rationale behind the administration of high-dose
glucocorticoid from embryo transfer onwards, and higher
implantation rates have been observed.19 Although the mech-
anism underlying the beneﬁcial effects of dexamethazone
(corticosteroids) is not exactly understood, it is apparent from
our data that dexamethazone (corticosteroids) therapy during
the follicular phase can enhance follicular development and
ovulation.12–16
Conclusions
Dexamethazone (corticosteroids) therapy combined with CC
can improve folliculogenesis, ovulation, and pregnancy rate in
CC resistant PCOS. Using CC alone by dose of 200 mg for 7 days
in PCOS patients resistant to 150 mg  CC showed no aberrant
difference in ovulation rate and pregnancy rate. It is apparent
from our data that dexamethazone (corticosteroids) therapy
during the follicular phase can enhance follicular develop-
ment and ovulation. So we  recommend use of dexamethazone
(corticosteroids) before shift to expensive gonadotropins in
PCOS females resistant to CC.
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